Pacira (PCRX)
NASDAQ:PCRX
Want to see PCRX full AI Analyst Report?
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
Select Model
Select Model
Rating:65Neutral
Price Target:
$25.00
▲(1.13% Upside)
Action:Reiterated
Date:06/12/26
The score is driven mainly by improved balance-sheet resilience and steady cash generation, reinforced by a constructive earnings call with reiterated guidance and ongoing buybacks. These positives are tempered by weak valuation support (very high P/E) and only neutral-to-soft technical momentum.
Positive Factors
Improved balance sheet and low leverage
Pacira’s materially reduced debt and improved debt-to-equity profile increase financial resilience and strategic optionality. A stronger balance sheet supports sustained R&D and commercial investment, funds share repurchases, and provides a buffer against clinical or reimbursement setbacks over the next 2–6 months.
Negative Factors
Volatile profitability and thin margins
Earnings volatility and currently thin operating/net margins limit predictability of sustained earnings power. This inconsistency lowers returns on equity, complicates long-term forecasting, and raises execution risk for funding both commercialization and development without eroding margins or relying on constant cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet and low leverage
Pacira’s materially reduced debt and improved debt-to-equity profile increase financial resilience and strategic optionality. A stronger balance sheet supports sustained R&D and commercial investment, funds share repurchases, and provides a buffer against clinical or reimbursement setbacks over the next 2–6 months.
Read all positive factors
Pacira Pharmaceuticals (PCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$878.35M
Dividend YieldN/A
Average Volume (3M)471.53K
Price to Earnings (P/E)175.8
Beta (1Y)0.80
Revenue Growth4.57%
EPS GrowthN/A
CountryUS
Employees788
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.12
Shares Outstanding39,334,984
10 Day Avg. Volume442,307
30 Day Avg. Volume471,528
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue1.58
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda9.78
Forecast
1Y Price Target
$29.75Price Target Upside20.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)2.88
Revenue Forecast (FY)$766.64M
Pacira Pharmaceuticals Business Overview & Revenue Model
Company Description
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable ...
How the Company Makes Money
Pacira primarily makes money by selling its marketed products to healthcare customers, generating revenue from product sales in the United States.
1) Product sales (core revenue stream)
- EXPAREL: Pacira’s largest commercial product is EXPAREL, a...
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call presented a predominately positive picture: the company reported solid top-line momentum across core products (EXPAREL, ZILRETTA, ioverao) with meaningful YoY growth, strengthened IP protection, expanded reimbursement coverage (110M+ covered lives), encouraging pipeline progress with near-term readouts, and healthy adjusted EBITDA and buyback activity. Near-term challenges include revenue mix impacts from a new GPO and winter storms, modest margin compression and elevated SG&A/R&D spending tied to strategic initiatives, and policy timing risk around NOPAIN’s scheduled 2027 expiration. On balance the positives — sustainable product growth, strengthened commercial and IP positions, active pipeline catalysts, and disciplined capital returns — outweigh the lowlights.Positive Updates
EXPAREL Net Sales and Volume Growth
EXPAREL net sales of $143.3M in Q1 2026 versus $136.5M in Q1 2025; reported volume growth of ~7% year-over-year, with continued momentum into 2026 driven by expanded reimbursement, a new product-specific J-code, non-opioid stewardship adoption, and protocol uptake.
Negative Updates
Revenue Mix and GPO Discounting Impact
EXPAREL Q1 revenue growth was partially offset despite volume growth due to a shift in vial mix and discounting from a third GPO that went live last year; company expects a similar delta between volume and revenue in Q2 and a narrowing midyear as the anniversary of that GPO passes.
Read all updates
Q1-2026 Updates
Positive
Negative
EXPAREL Net Sales and Volume Growth
EXPAREL net sales of $143.3M in Q1 2026 versus $136.5M in Q1 2025; reported volume growth of ~7% year-over-year, with continued momentum into 2026 driven by expanded reimbursement, a new product-specific J-code, non-opioid stewardship adoption, and protocol uptake.
Read all positive updates
Company Guidance
Pacira reiterated full‑year 2026 guidance of total revenues $745–770 million and EXPAREL net product sales of $600–620 million (plus an expected $7 million from a veterinary licensing agreement), with non‑GAAP gross margins of 77–79%, non‑GAAP R&D $105–115 million, non‑GAAP SG&A $320–340 million, stock‑based compensation $54–62 million and depreciation of about $30 million. The company said Q2 R&D should step up to the low‑$30 million range before returning closer to Q1 levels (~$25.4M) in Q3–Q4; Q1 metrics included EXPAREL net sales of $143.3M (≈7% volume growth), ZILRETTA $26.8M (+15%), ioverao $6.2M (+21%), consolidated non‑GAAP gross margin of 80% and adjusted EBITDA of ≈$40.2M. Pacira also executed $50M of share repurchases in Q1 (retiring ~2.2M shares), reduced outstanding shares to ~39.3M, and has $100M remaining on its repurchase authorization; it expects near‑term margin tailwinds from sale of lower‑cost EXPAREL inventory with Q4 margins modestly below full‑year guidance due to higher‑cost inventory and shutdown costs.Pacira Pharmaceuticals Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 734.86M | 726.41M | 700.97M | 674.98M | 666.82M | 541.53M |
| Gross Profit | 583.01M | 576.66M | 530.54M | 490.31M | 467.53M | 401.28M |
| EBITDA | 118.40M | 122.50M | 29.12M | 154.59M | 140.38M | 113.95M |
| Net Income | 5.14M | 7.03M | -99.56M | 41.95M | 15.91M | 41.98M |
Balance Sheet | ||||||
| Total Assets | 1.21B | 1.26B | 1.55B | 1.57B | 1.68B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 202.18M | 238.42M | 484.62M | 278.58M | 288.65M | 656.41M |
| Total Debt | 411.18M | 454.38M | 638.85M | 586.04M | 763.39M | 1.13B |
| Total Liabilities | 554.64M | 571.81M | 775.17M | 704.26M | 906.19M | 1.34B |
| Stockholders Equity | 653.89M | 693.11M | 778.35M | 870.13M | 775.01M | 730.41M |
Cash Flow | ||||||
| Free Cash Flow | 132.71M | 136.66M | 178.75M | 139.49M | 115.20M | 79.85M |
| Operating Cash Flow | 142.22M | 151.99M | 189.39M | 154.65M | 145.27M | 125.72M |
| Investing Cash Flow | 144.55M | 99.48M | -83.28M | 77.54M | -225.19M | -20.79M |
| Financing Cash Flow | -426.03M | -369.63M | 17.36M | -183.03M | -401.53M | 380.69M |
Pacira Pharmaceuticals Technical Analysis
Negative
24.72
Price Trends
23.63
Negative
22.92
Negative
23.50
Negative
Market Momentum
-0.22
Positive
40.54
Neutral
15.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Negative. The current price of 24.72 is above the 20-day moving average (MA) of 23.07, above the 50-day MA of 23.63, and above the 200-day MA of 23.50, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 15.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 71 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pacira Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.81B | 18.54 | 17.32% | ― | 37.03% | ― | |
69 Neutral | $1.09B | 14.36 | 26.74% | ― | 19.88% | 73.61% | |
68 Neutral | $829.39M | 10.76 | 10.23% | ― | -1.39% | -41.70% | |
65 Neutral | $878.35M | 175.85 | 0.73% | ― | 4.57% | ― | |
64 Neutral | $2.58B | -88.17 | -2.73% | ― | 16.29% | -145.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PCRX
Pacira Pharmaceuticals
22.33
-2.41
-9.74%
SUPN
Supernus Pharmaceuticals
44.38
12.39
38.73%
ANIP
ANI Pharmaceuticals
79.49
13.46
20.38%
AMPH
Amphastar Pharmaceuticals
18.81
-5.87
-23.78%
COLL
Collegium Pharmaceutical
33.54
3.66
12.25%
Pacira Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Pacira Pharmaceuticals Shareholders Back ESPP, Refresh Board Committees
Positive
Jun 11, 2026
At its June 9, 2026 annual meeting in Parsippany, N.J., Pacira stockholders approved an amended and restated 2014 Employee Stock Purchase Plan, adding 800,000 shares of common stock for employee purchases, and backed all three company director nom...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.